Get started
Author

Guillaume Baille

Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real‐World Observational Study ( FOSAPO )
2025 · Clément Desjardins, Quentin Salardaine, et al. · Movement Disorders Clinical Practice · 8
PDF
Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Insights From a Real-World Cohort
2026 · Clément Desjardins, Hélène de Saint Vaulry, et al. · Journal of Movement Disorders · 6
PDF
Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series
2025 · Guillaume Baille, Nathalie Patte‐Karsenti, et al. · Movement Disorders Clinical Practice · 6
PDF
Test-retest reliability of the six-minute walking distance measurements using FeetMe insoles by completely unassisted healthy adults in their homes
2023 · Andrey Mostovov, Damien Jacobs, et al. · PLOS Digital Health · 4
PDF
Validation of the six-minute walking distance measured by FeetMe® insoles
2023 · Andrey Mostovov, Damien Jacobs, et al. · BMC Digital Health · 3
PDF
Excellent reliability of the six-minute walking distance measured by FeetMe ® insoles at home
2023 · Andrey Mostovov, Damien Jacobs, et al. · medRxiv · 1
PDF
Dataset for "Excellent test-retest reliability of the six-minute walking distance measured by FeetMe insoles during tests conducted with a one-week interval by completely unassisted healthy adults in their homes."
2023 · Mostovov, Andrey, Jacobs, Damien, et al. · Zenodo (CERN European Organization for Nuclear Research)
Works count: 7
Citation count: 28
H-index: 4
I10-index:
Year
Topic
Type